Acquired immunodeficiency syndrome - Related lymphoma in the era of highly active antiretroviral therapy

Clinical Lymphoma

Volumn 4, Issue 2, 2003, Pages 86-92

  Thirlwell, Christina ^a   Sarker, Debashis ^a   Stebbing, Justin ^a   Bower, Mark ^a  

^a CHELSEA AND WESTMINSTER HOSPITAL   (United Kingdom)

Author keywords

Cerebral lymphoma; CHOP chemotherapy; HIV; Kaposi sarcoma; mBACOD chemotherapy; Non Hodgkin's lymphoma

Indexed keywords

ACICLOVIR; ANTINEOPLASTIC AGENT; ANTIRETROVIRUS AGENT; BLEOMYCIN; CD4 ANTIGEN; CYCLOPHOSPHAMIDE; CYTOTOXIC AGENT; DELAVIRDINE; DEXAMETHASONE; DIDANOSINE; DOXORUBICIN; EFAVIRENZ; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HEMOPOIETIC GROWTH FACTOR; INDINAVIR; LAMIVUDINE; METHOTREXATE; NELFINAVIR; NEVIRAPINE; PREDNISOLONE; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; UNINDEXED DRUG; VINCRISTINE; VINDESINE; ZALCITABINE; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; AGE; ANEMIA; BONE MARROW TOXICITY; BRAIN LYMPHOMA; BURKITT LYMPHOMA; CANCER CENTER; CANCER COMBINATION CHEMOTHERAPY; CANCER GRADING; CANCER INCIDENCE; CANCER STAGING; CANCER SURVIVAL; CARCINOGENESIS; CELL COUNT; CLINICAL FEATURE; CLINICAL TRIAL; COHORT ANALYSIS; DISEASE ASSOCIATION; DOSE RESPONSE; DRUG SAFETY; GENETIC PREDISPOSITION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; IMMUNOBLASTIC LYMPHOMA; IMMUNOCOMPETENCE; KAPOSI SARCOMA; MORTALITY; MUCOSA INFLAMMATION; NEUTROPENIA; NONHODGKIN LYMPHOMA; NONHUMAN; OPPORTUNISTIC INFECTION; PREDICTION; REVIEW; RISK FACTOR; TREATMENT OUTCOME;

EID: 0142248384     PISSN: 15269655     EISSN: None     Source Type: Journal    
DOI: 10.3816/CLM.2003.n.016     Document Type: Review

References (80)

1. Ziegler JL, Beckstead JA, Volberding PA, et al. Non-Hodgkin's lymphoma in 90 homosexual men. Relation to generalized lymphadenopathy and the acquired immunodeficiency syndrome. N Engl J Med 1984; 311:565-570.
2. Joint United Nations Programme on HIV/AIDS. Report on the global HIV/AIDS epidemic. Geneva: UNAIDS, 2002.
3. Palella FJ, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med 1998; 338:853-860.
4. Frisch M, Biggar RJ, Engels EA, et al. Association of cancer with AIDS-related immunosuppression in adults. JAMA 2001; 285:1736-1745.
5. Bower M, Powles T, Nelson M, et al. HIV-related lung cancer in the era of highly active antiretroviral therapy. AIDS 2003; 17:371-375.
6. Beral V, Peterman T, Berkelman R, et al. AIDS-associated non-Hodgkin lymphoma. Lancet 1991; 337:805-809.
7. Bigger RJ, Rosenberg PS, Cote T. Kaposi's sarcoma and non-Hodgkin's lymphoma following the diagnosis of AIDS. Multistate AIDS/Cancer Match Study Group. Int J Cancer 1996; 68:754-758.
8. Ledergerber B, Telenti A, Egger M, for the Swiss HIV Cohort Study. Risk of HIV related Kaposi's sarcoma and non-Hodgkin's lymphoma with potent antiretroviral therapy: prospective cohort study. Br Med J 1999; 319:23-24.
9. Inungu J, Melendez MF, Montgomery JP. AIDS-related primary brain lymphoma in Michigan, January 1990 to December 2000. AIDS Patient Care STDS 2002; 16:107-112.
10. Kirk O, Pedersen C, Cozzi-Lepri A, et al. Non-Hodgkin lymphoma in HIV-infected patients in the era of highly active antiretroviral therapy. Blood 2001; 98:3406-3412.
11. Buchbinder SP, Vittinghoff E, Colfax G, et al. Declines in AIDS incidence associated with highly active anti-retroviral therapy (HAART) are not reflected in KS and lymphoma incidence. In: Proceedings of the 2nd National AIDS Malignancy Conference; Bethesda, MD; 1998:S7.
12. Jacobson LP, Yamashita TE, Detels R, et al. Impact of potent antiretroviral therapy on the incidence of Kaposi's sarcoma and non-Hodgkin's lymphoma among HIV-1 infected individuals. J Acquir Immune Defic Syndr 1999; 21(suppl 1):34-41.
13. Rabkin CS, Testa MA, von Roenn JH. Kaposi's sarcoma and non-Hodgkin's lymphoma incidence and trends in AIDS Clinical Trial Group study participants. J Acquir Immune Defic Syndr 1999; 21(suppl 1):31-33.
14. Wilde JT, Lee CA, Darby SC, et al. The incidence of lymphoma in the UK haemophilia population between 1978 and 1999. AIDS 2002; 16:1803-1807.
15. International collaboration on HIV and cancer. Highly active antiretroviral therapy and incidence of cancer in human immunodeficiency virus-infected adults. J Natl Cancer Inst 2000; 92:1823-1830.
16. Goedert JJ, Cote TR, Virgo P, et al. Spectrum of AIDS-associated malignant disorders. Lancet 1998; 351:1833-1839.
17. Rabkin CS, Yang Q, Goedert JJ, et al. Chemokine and chemokine receptor gene variants and risk of non-Hodgkin's lymphoma in human immunodeficiency virus 1 infected individuals. Blood 1999; 93:1838-1842.
18. Dean M, Jacobson LP, McFarlane G, et al. Reduced risk of AIDS lymphoma in individuals heterozygous for the CCR5-delta32 mutation. Cancer Res 1999; 59:3561-3564.
19. Fong IW, Ho J, Toy C, et al. Value of long-term administration of acyclovir and similar agents for protecting against AIDS-related lymphoma: case-control and historical cohort studies. Clin Infect Dis 2000; 30:757-761.
20. Matthews G, Bower M, Mandalia S, et al. Changes in Aquired Immunodeficiency Syndrome-related lymphoma since the introduction of highly active antiretroviral therapy. Blood 2000; 96:2730-2734.
21. Grulich AE, Wan X, Law MG, et al. B-cell stimulation and prolonged immune deficiency are risk factors for non-Hodgkin's lymphoma in people with AIDS. AIDS 2000; 14:133-140.
22. Gerard L, Galicier L, Maillard A, et al. Systemic non-Hodgkin lymphoma in HIV-infected patients with effective suppression of HIV replication: persistent occurrence but improved survival. J Acquir Immune Defic Syndr 2002; 30:478-484.
23. Scadden DT, Zeira M, Woon A, et al. Human immunodeficiency virus infection of human bone marrow stromal fibroblasts. Blood 1992; 76:317-322.
24. Moses AV, Williams S, Heneveld ML, et al. Human immunodeficiency virus infection of bone marrow endothelium reduces induction of stromal hematopoietic growth factors. Blood 1996; 87:919-925.
25. Sarker D, Thirlwell C, Nelson M, et al. Leptomeningeal disease in AIDS related non-Hodgkin's lymphoma. AIDS 2003; 17:861-865.
26. Desai J, Mitnick RJ, Henry DH, et al. Patterns of central nervous system recurrence in patients with systemic human immunodeficiency virus-associated non-hodgkin lymphoma. Cancer 1999; 86:1840-1847.
27. Kaplan LD, Straus DJ, Testa MA, et al. Low dose compared with standard dose m-BACOD chemotherapy for non-Hodgkin's lymphoma associated with human immunodeficiency virus infection. N Engl J Med 1997; 336:1641-1648.
28. Cingolani A, Gastaldi R, Fassone L, et al. Epstein-Barr virus infection is predictive of CNS involvement in systemic AIDS-related non-Hodgkin's lymphomas. J Clin Oncol 2000; 18:3325-3330.
29. Levitt LJ, Dawson DM, Rosenthal DS, et al. CNS involvement in the non-Hodgkin's lymphomas. Cancer 1980; 45:545-552.
30. Levine AM, Wernz JC, Kaplan L, et al. Low dose chemotherapy with central nervous system prophylaxis and zidovudine maintenance in AIDS-related lymphoma. JAMA 1991; 266:84-88.
31. Tirelli U. Dose adjusted treatment in AIDS-related lymphoma. J Acquir Immune Defic Syndr 2000; 23(suppl):A12.
32. Kaplan LD, Abrams DI, Feigal E, et al. AIDS-associated non-Hodgkin's lymphoma in San Francisco. JAMA 1989; 261:719-724.
33. Gill PS, Levine AM, Krailo M, et al. AIDS-related malignant lymphoma: results of prospective treatment trials. J Clin Oncol 1987; 5:1322-1328.
34. Knowles DM, Chamulak GA, Subar M, et al. Lymphoid neoplasia associated with the acquired immunodeficiency syndrome (AIDS): The New York University Medical Center experience with 109 patients. Ann Intern Med 1988; 108:744-753.
35. Lowenthal DA, Straus DJ, Campbell SW, et al. AIDS-related lymphoid neoplasia. The Memorial Hospital Experience. Cancer 1988; 61:2325-2337.
36. Gisselbrecht C, Oksenhendler E, Tirelli U, et al. High-dose chemotherapy (LNH84) for HIV-associated non-Hodgkin's lymphoma. Am J Med 1993; 95:188-196.
37. Remick SC, Sedransk N, Haase RF, et al. Oral combination chemotherapy in conjunction with filgrastim (G-CSF) in the treatment of AIDS-related non-Hodgkin's lymphoma: evaluation of the role of G-CSF; quality-of-life analysis and long-term follow-up. Am J Hematol 2001; 66:178-188.
38. Aviles A, Nambo MJ, Halabe J. Treatment of acquired immunodeficiency syndrome-related lymphoma with a standard chemotherapy regimen. Ann Hematol 1999; 78:9-12.
39. Kersten MJ, Verduyn TJ, Reiss P, et al. Treatment of AIDS-related non-Hodgkin's lymphoma with chemotherapy (CNOP) and r-hu-G-CSF: clinical outcome and effect on HIV-1 viral load. Ann Oncol 1998; 9:1135-1138.
40. Weiss R, Huhn D, Mitrou P, et al. HIV-related non-Hodgkin's lymphoma: CHOP induction therapy and interferon-alpha-2b/zidovudine maintenance therapy. Leuk Lymphoma 1998; 29:103-118.
41. Davis AJ, Goldstein D, Milliken S. Long term follow-up of CEOP in the treatment of HIV related non-Hodgkin's lymphoma (NHL). Aust N Z J Med 1998; 28:28-32.
42. Schurmann D, Grunewald T, Weiss R, et al. Intensive treatment of AIDS-related non-Hodgkin's lymphomas with the MACOP-B protocol. Eur J Haematol 1995; 54:73-77.
43. Tirelli U, Errante D, Oksenhendler E, et al. Prospective study with combined low-dose chemotherapy and zidovudine in 37 patients with poor-prognosis AIDS-related non-Hodgkin's lymphoma. French-Italian Cooperative Study Group. Ann Oncol 1992; 3:843-847.
44. Sawka CA, Shepherd FA, Brandwein J, et al. Treatment of AIDS-related non-Hodgkin's lymphoma with a twelve week chemotherapy program. Leuk Lymphoma 1992; 8:213-220.
45. Gabarre J, Lepage E, Thyss A, et al. Chemotherapy combined with zidovudine and GM-CSF in human immunodeficiency virus-related non-Hodgkin's lymphoma. Ann Oncol 1995; 6:1025-1032.
46. Navarro JT, Ribera JM, Oriol A, et al. Influence of highly active anti-retroviral therapy on response to treatment and survival in patients with acquired immunodeficiency syndrome-related non-Hodgkin's lymphoma treated with cyclophosphamide, hydroxydoxorubicin, vincristine and prednisone. Br J Haematol 2001; 112:909-915.
47. Vaccher E, Spina M, di Gennaro G, et al. Concomitant cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy plus highly active antiretroviral therapy in patients with human immunodeficiency virus-related, non-Hodgkin lymphoma. Cancer 2001; 91:155-163.
48. Antinori A, Cingolani A, Alba L, et al. Better response to chemotherapy and prolonged survival in AIDS-related lymphomas responding to highly active antiretroviral therapy. AIDS 2001; 15:1483-1491.
49. Besson C, Goubar A, Gabarre J, et al. Changes in AIDS-related lymphoma since the era of highly active antiretroviral therapy. Blood 2001; 98:2339-2344.
50. Bower M, Matthews G, Powles T, et al. Changes in AIDS related lymphoma (ARL) in the era of highly active antiretroviral therapy (HAART). Proc Am Soc Clin Oncol 2000; 19:17a (Abstract #58).
51. Chow KU, Mitrou PS, Geduldig K, et al. Changing incidence and survival in patients with aids-related non-Hodgkin's lymphomas in the era of highly active antiretroviral therapy (HAART). Leuk Lymphoma 2001; 41:105-116.
52. Ratner L, Lee J, Tang S, et al. Chemotherapy for human immunodeficiency virus-associated non-Hodgkin's lymphoma in combination with highly active antiretroviral therapy. J Clin Oncol 2001; 19:2171-2178.
53. Boue F, Gabarre J, Gisselbrecht C, et al. CHOP chemotherapy plus rituximab in HIV patients with high grade lymphoma- results of an ANRS trial. Blood 2002; 100(suppl)470a (Abstract #1824).
54. Bower M, Stern S, Fife K, et al. Weekly alternating combination chemotherapy for good prognosis AIDS related lymphoma. Eur J Cancer 2000; 36:363-367.
55. Cortes J, Thomas D, Rios A, et al. Hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone and highly active antiretroviral therapy for patients with acquired immunodeficiency syndrome-related Burkitt lymphoma/leukemia. Cancer 2002; 94:1492-1499.
56. Oksenhendler E, Gerard L, Dubreuil ML, et al. Intensive chemotherapy (LNHIV-91 regimen) and G-CSF for HIV associated non-Hodgkin's lymphoma. Leuk Lymphoma 2000; 39:87-95.
57. Tirelli U, Spina M, Jaeger U, et al. Infusional CDE with rituximab for the treatment of human immunodeficiency virus-associated non-Hodgkin's lymphoma: preliminary results of a phase I/II study. Recent Results Cancer Res 2002; 159:149-153.
58. Gastaldi R, Martino P, Gentile G, et al. High dose of idarubicin-based regimen for diffuse large cell AIDS-related non-Hodgkin's lymphoma patients: a pilot study. Haematologica 2001; 86:1051-1059.
59. Little RF, Pearson D, Steinberg S, et al. Dose-adjusted EPOCH chemotherapy in previously untreated HIV-associated non-Hodgkin's lymphoma. Proc Am Soc Clin Oncol 1999; 18:10a (Abstract #33).
60. Sparano JA, Wiernik PH, Strack M, et al. Infusional cyclophosphamide, doxorubicin and etoposide in HIV and HTLV-1 related non Hodgkin's lymphoma. Blood 1993; 81:2810-2815.
61. Sparano JA, Wiernik PH, Hu X, et al. Pilot trial of infusional cyclophosphamide, doxorubicin and etoposide plus didanosine and filgrastim in patients with HIV associated non-Hodgkin's lymphoma. J Clin Oncol 1996; 14:3026-3035.
62. Little RF, Pittaluga S, Grant N, et al. Highly effective treatment of acquired immunodeficiency syndrome-related lymphoma with dose-adjusted EPOCH: impact of antiretroviral therapy suspension and tumor biology. Blood 2003; 101:4653-4659.
63. Sparano JA, Wiernik PH, Hu X, et al. Saquinavir enhances the mucosal toxicity of infusional cyclophosphamide, doxorubicin and etoposide in patients with HIV-associated non-Hodgkin's lymphoma. Med Oncol 1998; 15:50-57.
64. Sparano JA, Wiernik PH, Strack M, et al. Infusional cyclophosphamide, doxorubicin and etoposide in HIV-related non-Hodgkin's lymphoma: a follow-up report of a highly active regimen. Leuk Lymphoma 1994; 14:263-271.
65. Sparano JA, Lee S, Chen M, et al. Phase II trial of infusional cyclophosphamide, doxorubicin and etoposide (CDE) in HIV-associated non-Hodgkin's lymphoma: An Eastern Cooperative Oncology Group Trial (E1494). Proc Am Soc Clin Oncol 1999; 18:12a (Abstract #41).
66. Zanussi S, Simonelli C, D'Andrea M, et al. The effects of antineoplastic chemotherapy on HIV disease. AIDS Res Hum Retroviruses 1996; 12:1703-1707.
67. Powles T, Imami N, Nelson M, et al. Effects of combination chemotherapy and highly active antiretroviral therapy on immune parameters in HIV-1 associated lymphoma. AIDS 2002; 16:531-536.
68. Hakim FT, Cepeda R, Kaimei S, et al. Constraints on CD4 recovery post chemotherapy in adults. Blood 1997; 90:3789-3798.
69. Mackall CL. T-cell immunodeficiency following cytotoxic antineoplastic therapy: a review. Stem Cells 2000; 18:10-18.
70. Kaplan JE, Masur H, Holmes KK. Guidelines for preventing opportunistic infections among HIV-infected persons - 2002. Recommendations of the U.S. Public Health Service and the Infectious Diseases Society of America. MMWR Recomm Rep 2002; 51(RR-8):1-52.
71. Thirlwell C, Stebbing J, Nelson M, et al. CDE chemotherapy plus HAART for AIDS related non-Hodgkin's lymphoma. In: Proceedings of 6th International Congress on Drug Therapy in HIV Infection, 2002. vol. 94.
72. Levine AM, Sullivan Halley J, Pike MC, et al. Human immunodeficiency virus-related lymphoma. Prognostic factors predictive of survival. Cancer 1991; 68:2466-2472.
73. Rossi G, Donisi A, Casari S, et al. The International Prognostic Index can be used as a guide to treatment decisions regarding patients with human immunodeficiency virus-related non-Hodgkin lymphoma. Cancer 1999; 86:2391-2397.
74. Straus DJ, Huang J, Testa MA, et al. Prognostic factors in the treatment of human immunodeficiency virus-associated non-Hodgkin's lymphoma: analysis of AIDS Clinical Trials Group protocol 142-low-dose versus standard-dose m-BACOD plus granulocyte-macrophage colony-stimulating factor. J Clin Oncol 1998; 16:3601-3606.
75. Kentos A, Vekemans M, Van Vooren JP, et al. High-dose chemotherapy and autologous CD34-positive blood stem cell transplantation for multiple myeloma in an HIV carrier. Bone Marrow Transplant 2002; 29:273-275.
76. Krishnan A, Molina A, Zaia J, et al. Autologous stem cell transplantation for HIV-associated lymphoma. Blood 2001; 98:3857-3859.
77. Molina A, Krishnan AY, Nademanee A, et al. High dose therapy and autologous stem cell transplantation for human immunodeficiency virus-associated non-Hodgkin lymphoma in the era of highly active antiretroviral therapy. Cancer 2000; 89:680-689.
78. Gabarre J, Azar N, Autran B, et al. High-dose therapy and autologous haematopoietic stem-cell transplantation for HIV-1-associated lymphoma. Lancet 2000; 355:1071-1072.
79. Campbell P, Iland H, Gibson J, et al. Syngeneic stem cell transplantation for HIV-related lymphoma. Br J Haematol 1999; 105:795-798.
80. Gabarre J, Leblond V, Sutton L, et al. Autologous bone marrow transplantation in relapsed HIV-related non-Hodgkin's lymphoma. Bone Marrow Transplant 1996; 18:1195-1197.